Breast metastasis from primary lung adenocarcinoma in a young woman: A case report and literature review

Table 1 Breast metastasis from primary lung adenocarcinoma: Literature review 2000-2018

Ref.	Sex/age	Lung cancer	Breast metastasis	IHC markers of breast biopsy
Lee et al[3], 2000 (2 cases)	NA/NA	NA	NA	NA
Masmoudi et al[4], 2003	Female/54	NA	NA	NA
Ramar et al[5], 2003	Male/56	Right	Right	CK7-; CK20-; CAM 5.2-; ER-; PR-; CDP-
Yeh et al[6], 2004	Female/44	NA	Right	NA
Komorowski et al[7], 2005	NA/48	NA	NA	NA
Gómez-Caro et al[8] , 2006	Male/65	Left	Left	CK4+; CK7+; TTF-1-
Lee[1] , 2007	Female/64	NA	NA	NA
Ucar et al[9], 2007	Male/63	Left	Left	CK7+; TTF-1-
Ho et al[10], 2007	Male/71	Right	Left	NA
Rimner et al[11], 2007	Female/81	Left	Left	TTF-1+; ER-; PR-; HER2-
Fulciniti et al[12], 2008	Female/59	Right	Right	TTF-1+; ER-; PR-
Klingen et al[13], 2009	Female/79	NA	Left	CK7+; TTF-1+
	Male/70	NA	Right	CK7+; TTF-1+
Wang et al[14], 2009	Female/26	Right	Bilateral	TTF-1+
Babu et al[15], 2009	Female/51	NA	Left	CK7+; TTF-1+; ER-; PR-
Maounis et al[16], 2010	Female/73	Left	Left	TTF-1+; SP-A+; CEA+; CD15+; ER-; GCDFP15-; Mammaglobin-; CK 5/6 -; Calretinin -; CA125-; Thyroglobulin -
Yoon et al[17], 2010	Female/42	Left	Left	TTF-1+; E-cadherin+; ER-; PR-; p53-; HER2-
Nasit et al[18] ,2011	Female/42	Right	Bilateral	TTF-1+; CK7+; CEA+; GCDFP15-; ER-, PR-; CK5/6-; Thyroglobulin-
Fukumoto et al[19], 2011	Female/65	Left	Left	TTF-1+; ER-
Li et al[20], 2011	Female/53	Left	Left	TTF-1+; ER-; PR-
Ko et al[21], 2012	Female/47	Right	Right	TTF-1+; ER-; PR-; Mammaglobin-
Branica et al[22], 2012	Female/55	Left	Left	TTF-1+; CK7+; CK20-
Sato et al[23], 2012	Female/57	Right	Right	TTF-1+; CK 7+; SP-A+; MUC1+; ER-; PR-; MUC2 -; CK20-; GCDFP15-; HER2-
Ji et al[24], 2012	Female/49	Right	Left	TTF-1+; ER-; PR-; HER2-; Mammaglobin-; GCDFP15-
	Female/40	Left	Right	TTF-1+; ER-; PR-; HER2-; Mammaglobin-; GCDFP15-
Huang et al[25], 2013	Female/70	Left	Left	TTF-1+; ER-; PR-; GCDFP15-
	Female/48	Right	Right	NA
	Female/43	Right	Right	NA
	Female/54	Left	Left	NA
	Female/52	Left	Left	NA
	Female/43	Left	Left	NA
Sanguinetti et al[26], 2013	Female/43	Left	Left	TTF-1+; SP-A+; ER-; GCDFP15-; Mammaglobin-
Liam et al[27], 2013	Female/70	Right	Right	TTF-1+; ER-; PR-; HER2-
Sousaris et al[28], 2013	Female/55	Left	Left	TTF-1+; Napsin A+ER-; PR-
Jeong et al[29], 2014	Female/47	Left	Left	TTF-1+; CK7+; Napsin A+; ER-; PR-; HER2-; GCDFP15-; ALK-
Mirrielees et al[30], 2014	Female/58	Left	Left	TTF-1+; ER+; PR-; HER2-
Hachisuka et al[31], 2014	Male/60	Left	Right	TTF-1-; Napsin A-; ER-; PR-; HER2-; SP-A-; GCDFP15-
Dansin et al[32], 2015	Female/52	Left	Left	TTF1+; ER-; PR-; HER2-; GATA3-; GCDFP15-; PAX8-
Venkatesulu et al[33], 2015	Female/30	Right	Right	TTF1+; ER-; PR-; HER2-
Shen et al[34], 2015	Female/52	Right	Right	TTF-1+; CK7+; Napsin A+; ER-; PR-; GCDFP15-; Mammaglobin-
Gao et al[35], 2016	Female/45	Right	Right	TTF-1+; CK7+; Napsin A+; ROS1+; ER-; PR-; GCDFP15-; Mammaglobin-; HER2-; P63-; CK 5/6-; GATA3-
	Female/43	Right	Right	TTF-1+; CK7+; Napsin A+; ALK+; ER-; PR-; GCDFP15-; Mammaglobin-; HER2-; P63-; CK 5/6-; GATA3-
Bhanu et al[36], 2016	Female/30	Right	Right	TTF-1+; GCDFP15-; Mammaglobin-
Erhamamci et al[37], 2016	Male/74	Right	Right	NA
Ninan et al[38], 2016	Female/67	Right	Right	CK7+; TTF-1+; Napsin A+; GCDFP15-; GATA3-
Ozturk et al[39], 2017	Male/63	Left	Left	TTF-1+; Napsin A+; Mucin +; P63-
Cserni[40], 2017	Female/60	Right	Left	CK7+; TTF-1+; Napsin A+; ER+; PR-; HER2-; GCDFP15-; Mammaglobin-; GATA3-; P63-
Zahedi et al[41], 2017	Female/45	Left	Right	CK7+; TTF-1+; Napsin A+; ER-; PR-; HER2-; GCDFP15-; CK20-; Mammaglobin-; Calretinin-; WT1-; CDX2-; Thyroglobulin-
Al-Zawi et al[42], 2017	Female/84	Left	Left	CK7+; TTF-1+; CK5-; P63-; ER-; PR-; GCDFP15 -; HER2-; ALK-
Ali et al[43], 2017	Female/64	NA	NA	TTF-1-; ER-; HER2-
	Female/70	NA	NA	TTF-1+; Napsin A+; ER+; HER2-
	Female/72	NA	NA	TTF-1+; Napsin A+; ER-; HER2-
	Female/59	NA	NA	TTF-1+; ER-; HER2-
	Female/63	NA	Bilateral	TTF-1+; Napsin A+; ER-; HER2-
	Female/45	NA	NA	TTF-1+; Napsin A-; ER-; HER2-
	Female/65	NA	NA	TTF-1+
	Female/70	NA	NA	ER-
	Female/69	NA	NA	TTF-1+; Napsin A+; ER-; HER2-
	Female/65	NA	NA	TTF-1-; ER-
	Female/64	NA	NA	TTF-1-; Napsin A-; ER-; HER2-
Ota et al[44], 2018	Female/69	Left	Left	CK7+; CK 20-; TTF-1+; Napsin A+; ER-; PR-; HER2-; GCDFP15-
Our case	Female/29	Right	Right	AE1AE3+; CK7+; TTF-1+; Napsin A+; P63-; CK20-; ER-; PR-; GATA3-; HER2-

IHC: Immunohistochemistry; NA: Not available; ER: Estrogen receptor; PR: Progesterone receptor; HER2: Human epithelial growth factor receptor 2; TTF-1: Thyroid transcription factor 1; CK7: Cytokeratin 7; CK20: Cytokeratin 20; CK4: Cytokeratin-4; GCDFP15: Gross cystic disease fluid protein 15; SP-A: Surfactant A; CK5/6: Cytokeratin 5/6; MUC1: Mucin 1; MUC2: Mucin 2; ALK: Anaplastic lymphoma kinase; GATA3: GATA-binding protein 3; PAX8: Paired box gene 8; P63: Transformation-related protein 63.